Skip to main content

Table 1 Demographic and baseline characteristics.

From: Effects of external application of compound Qingbi granules on acute gouty arthritis with dampness-heat syndrome: a randomized controlled trial

Variable Control group n = 27 Treatment group1 n = 28 Treatment group2 n = 29
Age (years, mean ± SD) 45.00 ± 3.17 48.00 ± 7.05 46.00 ± 7.49
Men, n (%) 19 (70.37%) 20 (71.43%) 19 (65.52%)
History of gout (years, median (range)) 3.00 (0–9) 3.00 (0–10) 3.00 (0–11)
BMI (kg/m2, mean ± SD) 32.00 ± 5.07 31.07 ± 4.00 32.05 ± 5.99
Uric acid (pre-treatment) (μmol/L, mean ± SD) 480.04 ± 98.04 470.14 ± 90.12 479.97 ± 97.96
Onset time, n (%)
 ≤ 24 h 3 (11.11%) 4 (14.29%) 5 (17.24%)
 24–48 h 9 (33.33%) 8 (28.57%) 8 (27.59%)
 48–72 h 15 (55.56%) 16 (57.14%) 16 (55.17%)
Index joint, n (%)
 Metatasophalangeal joint 1 4 (14.81%) 3 (10.71%) 4 (13.79%)
 Other foot joints, 5 (18.52%) 5 (17.86%) 9 (31.03%)
 Ankle 5 (18.52%) 6 (21.43%) 7 (24.14%)
 Knee 6 (22.22%) 9 (32.14%) 7 (24.14%)
 Wrist 1 (3.70%) 1 (3.57%) 0
 Hand 2 (7.41%) 3 (10.71%) 2 (6.90%)
 Elbow 1 (3.70%) 0 0
 Multiple joints 3 (11.11%) 1 (3.57%) 0
Joint swelling, n (%)
 No swelling 0 2 (7.14%) 0
 Palpable 6 (22.22%) 8 (28.57%) 8 (27.59%)
 Visible 6 (22.22%) 8 (28.57%) 10 (34.48%)
 Bulging beyond joint margins 15 (55.56%) 10 (35.71%) 11 (37.93%)
Activity, n (%)
 No restricted 0 0 0
 Moderate restricted 5 (18.52%) 7 (25.00%) 9 (31.03%)
 Significantly restricted 9 (33.33%) 11 (39.29%) 10 (34.48%)
 Unbearable, cannot take care of themselves 13 (48.14%) 10 (35.71%) 10 (34.48%)
 Smoke use, n (%) 5 (18.52%) 7 (25.00%) 6 (20.69%)
 Drink, n (%) 10 (37.04%) 11 (39.29%) 11 (37.93%)
  1. aNo significant differences were found in the demographic data of all groups (P all  > 0.05)